A social media post by parentunelive on March 1, 2026, highlighting the potential of cord blood stem cells has coincided with growing attention to cord blood banking as a means of safeguarding future health options.
Umbilical cord blood, once routinely discarded as medical waste, is now recognized as a rich source of Hematopoietic Stem Cells (HSCs). These cells possess the ability to develop into red blood cells, white blood cells, and platelets, offering potential treatments for a range of diseases. Currently, cord blood stem cells are FDA-approved to treat over 80 life-threatening conditions, including leukemias, lymphomas, sickle cell anemia, and immune deficiencies, according to StemCyte.
The process of cord blood banking involves collecting and storing the blood remaining in the umbilical cord and placenta after birth. Collection is a brief procedure, taking only a few minutes and is painless for both mother and baby. Doctors clamp the umbilical cord, cut it, and then insert a needle to collect at least 40 milliliters of blood, which is then sent to a laboratory for testing and storage.
Parents have several options for storage. Public cord banks offer free storage, making the donated blood available for anyone in demand, and may utilize the donations for research. Private cord banks, like Cells4Life and StemCyte, offer storage for a fee, preserving the stem cells specifically for the child and potentially for family members. StemCyte currently charges $995 for cord blood and tissue processing, with a promotional code available.
StemCyte reports having provided one out of every 26 cord blood transplants worldwide, and has participated in more clinical trials than any other cord blood bank. The company also operates both private and public banking options, offering what they call “Public Bank Access Plus.”
The potential of cord blood banking extends beyond currently approved treatments. Researchers are actively exploring emerging therapies, positioning cord blood banking as a potential investment in future medical advancements. Americord Registry notes that 2026 is a pivotal year for cord blood banking due to these advancements.
A Cord Blood Preservation in-person class is scheduled for March 12, 2026, in San Diego, CA, hosted by StemCyte.
The FDA recently approved StemCyte’s Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product, signaling further development in the field.
